Aa
A
A
A
Close
Hepatitis C Community
13.4k Members
Avatar universal

Pegasus vs peg intron with Vic 3x TX

If taking Vic 3xtx
do u get to pick Pegasus or peg intron
Or do u have no choice?

Cause another thread about int fevers said that a study done in Italy showed better results with Pegasus
Thank u!
11 Responses
1669790 tn?1333666195
What interferon did you use for your first two trts?  This might have some bearing on the choice for the next trt.  Hopefully some that have undergone more than one trt can help to explain what they chose and why.  
Avatar universal
Very similar results. 2% is well within the margin of error. Pegasys however seems to be tolerated better by the majority of people.

http://www.drugs.com/clinical_trials/victrelis-boceprevir-merck-s-investigational-medicine-added-peginterferon-alfa-2a-ribavirin-11404.html

"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that final results from a Phase III study of VICTRELIS™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a (Pegasys®) and ribavirin therapy demonstrated significantly higher sustained virologic response (SVR)1 rates in adult patients who failed previous treatment for chronic hepatitis C virus (HCV) genotype 1 compared to a control group receiving peginterferon alfa-2a and ribavirin alone, the primary endpoint of the 48-week study. Significantly more patients in the treatment group receiving VICTRELIS achieved SVR, 64 percent (86/134) vs. 21 percent (14/67) for control, p<0.0001; and fewer patients receiving VICTRELIS relapsed after the end of treatment, 12 percent (11/95) vs. 33 percent (7/21) for control. These results were presented for the first time today as part of a late-breaker poster session [Poster #1366] at The International Liver Congress™ / 46th European Association for the Study of the Liver (EASL) annual meeting.

"In this study, the addition of VICTRELIS to peginterferon alfa-2a and ribavirin resulted in approximately a three-fold increase in sustained virologic response in patients who were previous nonresponders or relapsers to standard hepatitis C therapy," said Steven L. Flamm, M.D., professor in medicine-hepatology and surgery, Northwestern University Feinberg School of Medicine, Chicago. "These results are similar to those seen with the 48-week treatment regimen of VICTRELIS added to peginterferon alfa-2b and ribavirin in HCV RESPOND-2, a pivotal Phase III study. Taken together, these studies showed that VICTRELIS combined with either peginterferon alfa-2a or alfa-2b and ribavirin achieved significantly higher SVR rates in chronic HCV genotype 1 patients who failed prior therapy compared to peginterferon and ribavirin alone."

As published in today's edition of The New England Journal of Medicine, in the HCV RESPOND-2 study in patients who failed prior therapy, the addition of VICTRELIS to peginterferon alfa-2b (PEGINTRON®) and ribavirin in a 48-week regimen achieved an SVR rate of 66 percent (107/161) compared to 21 percent for control (17/80), p<0.0001. The relapse rate was 12 percent (14/121) for the group receiving VICTRELIS compared to 32 percent (8/25) for control.

VICTRELIS added to peginterferon alfa-2a and ribavirin

The study of VICTRELIS added to peginterferon alfa-2a and ribavirin (PEG2a/R) presented at EASL was a Phase III, placebo-controlled trial in which 201 adult patients with chronic HCV genotype 1 infection who were either relapsers or nonresponders to prior peginterferon and ribavirin therapy were randomized to one of two 48-week treatment groups in a 1:2 ratio. The control group received a 4-week lead-in of PEG2a/R followed by placebo + PEG2a/R for 44 weeks. The group treated with VICTRELIS received a 4-week lead-in of PEG2a/R followed by the addition of VICTRELIS for 44 weeks. Peginterferon alfa-2a was administered subcutaneously at a dose of 180 mcg once weekly in combination with ribavirin 1,000-1,200 mg/day orally based on patient weight in a divided daily dose. VICTRELIS was administered orally at a dose of 800 mg three times daily. Patients in the study with detectable virus (HCV-RNA) at treatment week 12 were considered treatment failures and discontinued all therapy."
Avatar universal
You can use vic with either peg interferon. Roche is pushing the pegasys/victrelis combo and merck is pushing the pegintron/victrelis combo.

http://pharmacyblogbuy.com/can-merckroche-hep-c-deal-put-victrelis-combo-on-top/

"Can Merck/Roche hep C deal put Victrelis combo on top?
What’s better than Big Pharma marketing power? Big Pharma marketing power times two. Merck has tapped Roche to help sell its new hepatitis C drug Victrelis, aiming to combat the perceived edge of soon-to-be-approved competitor Incivek from Vertex Pharmaceuticals and Johnson & Johnson.
What’s interesting about this co-promotion deal is that Merck and Roche make rival hepatitis C drugs, Peg-Intron and Pegasys. They’re interferon injections are part of the standard two-drug therapy for the disease. Victrelis is an add-on, creating a three-drug cocktail that’s proven to be more effective at curing hep C than the standard two-drug combo and work more quickly than the standard therapy, which has its share of unpleasant side effects.
Merck will market Victrelis as an addition to the Peg-Intron cocktail, while Roche will promote its combination with Pegasys. And Pegasys has muscle; it currently owns about three-quarters of the interferon market in hepatitis C, Bloomberg says. Plus, Merck’s trials for Victrelis tested the drug in combination with Peg-Intron, so having Roche put its stamp on Victrelis as a Pegasys add-on could help offset the lack of data there. That’s what Sanford Bernstein’s Tim Anderson figures: “Now, with Roche on board, this potential shortcoming gets more than removed, in our opinion.”
Together, the two companies will be working to shoulder Incivek aside. “In essence, the Merck-Roche agreement effectively tries to shut telaprevir (Incivek) out of the market to some degree,” Anderson said (as quoted by Medical Marketing & Media). The marketing deal covers the U.S. right now, but the companies said it could be expanded to other markets as well."
Avatar universal
Thank u all
I didn't do earlier TX I am naive

I just want to do whichever intereon is the most successful since I am ib/ TT
With reduced odds to begin with

So if one is better I will request it over the other

Anyone else with thoughts please feel free to chime in and again thank you
1669790 tn?1333666195
Oops, my bad.  I misread your post thinking this was round 3 for you.  

As Dave pointed out there seems to be little difference in results, however the Pegasys appears to be tolerated better by many members on the forum.  I'd lean toward Pegasys for this reason, but it would be good to hear from others that have done both for their opinions.  I'd certainly be listening closely to my doctor on this one.  Good luck choosing and starting trt soon.
Avatar universal
TY flcylist
Yes I want the easiest to tol and most effective of them :-)
Have an Answer?
Top Hepatitis Answerers
317787 tn?1473362051
DC
683231 tn?1467326617
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.
Smoking substitute may not provide such a healthy swap, after all.